BORTEZOMIB IS A SUBSTRATE OF CYTOCHROME P450 ENZYME 3A4, 2C19 AND 1A2.
CYP3A4 INHIBITORS:
CO-ADMINISTRATION OF KETOCONAZOLE, RITONAVIR, STRONG CYP3A4 INHIBITOR, INCREASE PLASMA CONC. OF BORTEZOMIB BY 35.
CYP2C19 INHIBITORS:
CO-ADMINISTRATION OF OMEPRAZOLE, A STRONG INHIBITOR OF CYP2C19, HAD NO EFFECT ON THE EXPOSURE OF BORTEZOMIB.
CYP3A4 INDUCERS:
CO-ADMINISTRATION OF RIFAMPIN, A STRONG CYP3A4 INDUCER, IS EXPECTED TO DECREASE PLASMA CONC. OF BORTEZOMIB BY AT LEAST 45%.
ST. JOHN'S WORT (HYPERICUM PERFORATUM) MAY DECREASE BORTEZOMIB EXPOSURE UNPREDICTABLY.
CO-ADMINISTRATION OF DEXAMETHASONE, A WEAK CYP3A4 INDUCER, HAD NO EFFECT ON THE EXPOSURE OF BORTEZOMIB.
MELPHALAN-PREDNISONE CO-ADMINISTRATION INCREASED THE EXPOSURE OF BORTEZOMIB BY 17%, HOWEVER, THIS INCREASE IS UNLIKELY TO BE CLINICALLY RELEVANT.